American College of Cardiology Presentation Highlights Promising Results Showing Potential to Reduce Coronary Inflammation with Abcentra's Orticumab

/PRNewswire/ -- Abcentra LLC, a clinical-stage biopharmaceutical company specializing in coronary artery disease, presented the latest results from a Phase 2a...